About the Company
Vaxart, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of oral recombinant vaccines administered using temperature-stable tablets that can be stored and shipped without refrigeration, eliminating the need for needle injection. Its development programs for oral vaccine delivery (Vector-Adjuvant-Antigen Standardized Technology known as VAAST) include prophylactic, enteric-coated tablet vaccines for inhibiting norovirus, seasonal influenza, respiratory syncytial virus, and human papillomavirus. It was founded in 2004 by Sean Tucker. Originally incorporated as West Coast Biologicals, Inc. in California in 2004, the company later changed its name to Vaxart, Inc. in July 2007, after reincorporating in Delaware. A significant development in the company's history was the reverse merger with Aviragen Therapeutics, Inc. on February 13, 2018, which led to Vaxart becoming a wholly owned subsidiary of Aviragen. Post-merger, the company continued as Vaxart, Inc. Vaxart's development portfolio includes a range of oral vaccines targeting infectious diseases such as norovirus, COVID-19, and seasonal influenza, as well as therapeutic vaccines like those targeting HPV. The company has achieved significant milestones in its vaccine development, including completing Phase 1 trials for its COVID-19 vaccine candidate and embarking on Phase 2 studies. Vaxart’s vaccines are designed to elicit not only systemic immune responses but also mucosal and T cell responses, which may enhance protection against specific diseases and offer potential benefits for certain cancers and chronic viral infections. The tablet form of these vaccines represents a significant advancement in vaccine administration, potentially improving patient acceptance and resolving distribution challenges.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Vaxart, Inc.
Vaxart, Inc. (NASDAQ:VXRT) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 13, 2025 Vaxart, Inc. beats earnings expectations. Reported EPS is $-0.07, ...
Concerned Vaxart Stockholders Unite to Oppose Vaxart’s Latest Reverse Stock Split and Defend Stockholder Rights
Urge Stockholders to Vote “AGAINST” Reverse Stock Split at Upcoming Special Meeting Call for Accountability Given Board’s Pattern of Disregarding ...
Vaxart Discusses Reverse Stock Split Proposal
Vaxart ( ($VXRT) ) has provided an announcement. On August 20, 2025, Vaxart, Inc. held a virtual fireside chat with stockholders to discuss a ...
Vaxart Inc (VXRT) Q2 2025 Earnings Call Highlights: Revenue Surge Amidst Operational Challenges
Vaxart Inc (VXRT) reports a significant revenue increase but faces hurdles with trial suspensions and NASDAQ compliance ...
Vaxart, Inc. (VXRT.MX) - Yahoo Finance
As of May 6 at 12:06 PM CST. Market Open. Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will ...
Vaxart, Inc. to Host Conference Call for Business Update and ... - Nasdaq
Vaxart, Inc. announced that it will provide a business update and financial results for the year ending December 31, 2024, after the market closes on March 20, 2025.
Vaxart, Inc. (VXRT)
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: ...
Vaxart, Inc. (NB11.F) Latest Stock News & Headlines - Yahoo Finance
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on November 15, 2024, the Compensation Committee of the ...
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635 ...
--Vaxart, Inc. today announced that on August 26, 2024, the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 32,250 shares of its common ...
Vaxart Looks To Be On The Verge Of Breaking Out Of A Pattern
Vaxart Inc. (NASDAQ:VXRT) shares are trading lower Monday, possibly after retail traders were able to push the stock higher. The stock looks to be almost breaking out of a technical pattern.
Vaxart, Inc. Announces Management Change - Seeking Alpha
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (VXRT) today announced a change in management. Effective immediately Andrei Floroiu, President and Chief Executive ...
OTC Markets Group Welcomes Vaxart, Inc. to OTCQX
NEW YORK, July 08, 2025 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCM) (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vaxart ...
Similar Companies
Loading the latest forecasts...